Vaxart highlights progress of COVID-19, norovirus, influenza programs

Vaxart (VXRT) provided business updates as the Company continues to advance its oral pill vaccine platform. COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration review of sentinel cohort 30-day safety data; Norovirus program to proceed with Phase 1 study following scientific advisory board and FDA feedback; Trial to initiate the first half of 2025 with topline data expected as early as mid-2025. New avian influenza vaccine candidate being tested in preclinical studies